Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $754.8 million.

  • Takeda Pharmaceutical's EPS (Basic) fell 1084.56% to $754.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $754.8 million, marking a year-over-year decrease of 1084.56%. This contributed to the annual value of $1.6 billion for FY2025, which is 24724559745740.64% up from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's EPS (Basic) is $754.8 million, which was down 1084.56% from $9.8 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EPS (Basic) peaked at $9.8 billion during Q3 2023, and registered a low of -$77.2 million during Q1 2022.
  • Over the past 5 years, Takeda Pharmaceutical's median EPS (Basic) value was $1.3 billion (recorded in 2022), while the average stood at $2.3 billion.
  • In the last 5 years, Takeda Pharmaceutical's EPS (Basic) tumbled by 10942.76% in 2022 and then surged by 1245541.31% in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EPS (Basic) (Quarter) stood at $374.9 million in 2021, then skyrocketed by 72.39% to $646.3 million in 2022, then soared by 161.77% to $1.7 billion in 2023, then crashed by 49.96% to $846.6 million in 2024, then fell by 10.85% to $754.8 million in 2025.
  • Its EPS (Basic) stands at $754.8 million for Q4 2025, versus $9.8 billion for Q3 2025 and $2.7 billion for Q2 2025.